Article

Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy.

Division of Human Nutrition, Wageningen University, Wageningen, Gelderland, Netherlands
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 07/1994; 78(6):1515-20. DOI: 10.1210/jc.78.6.1515
Source: PubMed

ABSTRACT In 70 healthy obese subjects (37 men and 33 premenopausal women; aged 27-51 yr; body mass index, 28-38 kg/m2), associations between the initial amount of visceral fat and sex hormone levels were studied as well as between changes that occurred in response to a 4.2 mJ/day deficit diet for 13 weeks. Magnetic resonance imaging was used to quantify the visceral fat depot. In women, an abundance of visceral fat was significantly associated with diminished levels of sex hormone-binding globulin and free 17 beta-estradiol/free testosterone (T) ratio and to elevated levels of free T after adjustment for age and total fat mass. In men, no significant relationships could be found between visceral fat accumulation and any of the sex hormones. Mean total fat loss was 11.3 +/- 3.3 (+/- SD) kg. In women, loss of visceral fat was significantly related to rises in the sex hormone-binding globulin level and the free 17 beta-estradiol/free T ratio independent of total fat loss, whereas in men, only the association between visceral fat loss and increased estrone level reached statistical significance. In conclusion, in obese premenopausal women, visceral fat predominance seems to be related to a relatively increased androgenicity. In obese men, sex steroid levels appear not to depend on the amount of visceral fat. In obese women, but not in obese men, visceral fat loss seems to be accompanied by a relative reduction in androgenicity.

1 Follower
 · 
164 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Androgen excess in women and androgen deficiency in men facilitate abdominal adiposity and related metabolic disorders. Moreover, obesity-associated gonadal dysfunction consists of hyperandrogenism in women but hypogonadism in men. We have reviewed the existing evidence on the interplay between sex steroids, adipose tissue and lean mass distribution, and developed a novel hypothesis to explain these apparent paradoxes. We hypothesize that the most beneficial adipose tissue distribution and function is that of normal women, who have low androgen and high estrogen concentrations. Any imbalance favoring an increase in androgen levels in women, and the very high androgen levels characteristic of healthy men, influence adipose tissue distribution and function. Sex steroids determine a favorable (female) or unfavorable (male) body fat distribution and function. However, sex hormones also provide defensive mechanisms against visceral fat accumulation: androgens increase lean and muscle mass in men, decreasing the amount of visceral fat relative to total body mass and its negative consequences, whereas estrogens determine the metabolically safer deposition of body fat into the subcutaneous gluteal-femoral depot in women. This delicate equilibrium may be altered by the presence of gonadal dysfunction, a sedentary life-style or the normal ageing process leading to sarcopenia, and by the development of obesity leading to abdominal adiposity and metabolic disorders in both sexes. In conclusion, sex hormones and gonadal dysfunction play important roles in the pathogenesis of diabesity and its metabolic associations.
    Human Reproduction 08/2014; 29(10). DOI:10.1093/humrep/deu198 · 4.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Low testosterone is frequently found in obese men over all ages. The relationship between obesity and low testosterone levels in men is complex and apparently bidirectional. Low testosterone and SHBG levels predict the development of central obesity and are associated with an increased risk of developing metabolic syndrome and type 2 diabetes and higher mortality rate for cardiovascular disease. By contrast, obesity predicts low total and free testosterone levels. Several mechanisms interfering with the hypothalamic pituitary gonadal axis have been suggested as responsible for low testosterone production in obese subjects without, however, any clear understanding. Life-style measures achieving a substantial weight loss may increase testosterone levels, whereas clear data on whether exogenous testosterone treatment in obese men, without an established hypogonadic state, may improve body fat content, visceral adiposity and insulin resistance are still missing. Further studies on the pathophysiological mechanisms and on the efficacy of testosterone treatment in obese men with low testosterone levels are needed.
    12/2012; 1(4). DOI:10.1007/s13679-012-0029-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With increasing modernization and urbanization of Asia, much of the future focus of the obesity epidemic will be in the Asian region. Low testosterone levels are frequently encountered in obese men who do not otherwise have a recognizable hypothalamic-pituitary-testicular (HPT) axis pathology. Moderate obesity predominantly decreases total testosterone due to insulin resistance-associated reductions in sex hormone binding globulin. More severe obesity is additionally associated with reductions in free testosterone levels due to suppression of the HPT axis. Low testosterone by itself leads to increasing adiposity, creating a self-perpetuating cycle of metabolic complications. Obesity-associated hypotestosteronemia is a functional, non-permanent state, which can be reversible, but this requires substantial weight loss. While testosterone treatment can lead to moderate reductions in fat mass, obesity by itself, in the absence of symptomatic androgen defi ciency, is not an established indication for testosterone therapy. Testosterone therapy may lead to a worsening of untreated sleep apnea and compromise fertility. Whether testosterone therapy augments diet- and exercise-induced weight loss requires evaluation in adequately designed randomized controlled clinical trials.
    Asian Journal of Andrology 12/2013; 16(2). DOI:10.4103/1008-682X.122365 · 2.53 Impact Factor